IL-18 revives dysfunctional CAR-T cells

作者：Yan-Ruide Li, Yichen Zhu, Lili Yang · 发表于：Trends in cancer · 年份：2025 · DOI：10.1016/j.trecan.2025.06.008 · 被引用次数：18 · 研究领域：CAR-T cell therapy research、Immune Cell Function and Interaction、T-cell and B-cell Immunology

IL-18-armored chimeric antigen receptor (CAR)-engineered T (18.CAR-T) cells have demonstrated enhanced antitumor efficacy in lymphoma patients refractory to conventional CAR-T therapy. Unraveling the mechanisms behind this potent enhancement and mitigating associated toxicities could unlock a new era of next-generation CAR-T therapies with superior effectiveness and broader clinical impact.